3D Engineered Tissue Constructs for In Vitro Germinal Centers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models for studying germinal centers and vaccine responses are limited by their two-dimensional nature, which fails to accurately replicate the complex interactions and functions of follicular dendritic cells (FDCs) in three-dimensional environments, affecting the generation of humoral immune responses.
Innovation Solution
An artificial immune system is developed with a three-dimensional engineered tissue construct incorporating follicular dendritic cells, B cells, and T cells, allowing for the assessment of allergens, immunogens, and vaccines without animal testing, utilizing a collagen matrix or other extracellular matrix materials to enhance the functionality and longevity of FDCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If two-dimensional culture plates are used for in vitro germinal centers, then the model is simpler to establish and maintain, but the accuracy of replicating FDC interactions and humoral immune response generation is reduced
Solution Approach 1:
The patent transitions from two-dimensional culture plates to three-dimensional engineered tissue constructs. This dimensional change enables FDCs to form realistic network structures and spatial arrangements that mimic in vivo germinal centers, thereby improving the accuracy of FDC-B cell-T cell interactions while maintaining experimental tractability through standardized construct designs
2Measurement precision
If three-dimensional engineered tissue constructs are used, then the accuracy of humoral immune response generation is improved, but the complexity of the system increases
Solution Approach 1:
The patent segments the immune system components into distinct functional modules: FDC networks for antigen presentation, B cell zones for antibody production, and T cell areas for helper functions. This modular segmentation allows each component to be optimized independently while maintaining overall system accuracy, reducing the management complexity despite the three-dimensional architecture
3Ease of operation
If FDCs are cultured in two-dimensional environments, then the culture conditions are easier to control, but the functionality and longevity of FDCs are reduced
Solution Approach 1:
The patent employs composite extracellular matrix materials combining natural components (collagen, fibrin, hyaluronic acid) to create a three-dimensional scaffold that provides biochemical and biophysical cues essential for FDC survival and function. This composite approach mimics the native tissue environment, extending FDC longevity and functionality while maintaining controllable culture conditions through standardized matrix formulations
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention incorporates germinal centers (GCs) into three- dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens and immunogenes, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing follicular dendritic cells (FDCs) and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days).